BIOXCEL THERAPEUTICS INC (BTAI) Stock Price, Quote, News and Overview
NASDAQ:BTAI - Nasdaq - US09075P2048 - Common Stock - Currency: USD
BTAI Quote, Performance and Key Statistics
1.77
-0.26 (-12.81%)
The current stock price of BTAI is 1.77 USD. In the past month the price increased by 43.9%. In the past year, price decreased by -91.36%.
BTAI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.75 | 322.03B | ||
| AMGN | AMGEN INC | 13.35 | 149.02B | ||
| GILD | GILEAD SCIENCES INC | 14.3 | 137.67B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 113.33B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.76 | 56.25B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 42.09B | ||
| ARGX | ARGENX SE - ADR | 97.42 | 34.20B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.16 | 26.09B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.65B | ||
| NTRA | NATERA INC | N/A | 22.93B | ||
| BIIB | BIOGEN INC | 7.97 | 18.47B | ||
| INSM | INSMED INC | N/A | 18.12B |
Related stock screener links
About BTAI
Company Profile
BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. The company is headquartered in New Haven, Connecticut and currently employs 37 full-time employees. The company went IPO on 2018-03-08. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Company’s most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders. The company is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimers disease in the at-home setting and in care facilities. Its most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
Company Info
BIOXCEL THERAPEUTICS INC
555 Long Wharf Dr
New Haven CONNECTICUT 06511 US
CEO: Vimal Mehta
Employees: 37
Phone: 12036438060
BIOXCEL THERAPEUTICS INC / BTAI FAQ
What is the stock price of BIOXCEL THERAPEUTICS INC today?
The current stock price of BTAI is 1.77 USD. The price decreased by -12.81% in the last trading session.
What is the ticker symbol for BIOXCEL THERAPEUTICS INC stock?
The exchange symbol of BIOXCEL THERAPEUTICS INC is BTAI and it is listed on the Nasdaq exchange.
On which exchange is BTAI stock listed?
BTAI stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BIOXCEL THERAPEUTICS INC stock?
11 analysts have analysed BTAI and the average price target is 17.75 USD. This implies a price increase of 902.71% is expected in the next year compared to the current price of 1.77. Check the BIOXCEL THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BIOXCEL THERAPEUTICS INC worth?
BIOXCEL THERAPEUTICS INC (BTAI) has a market capitalization of 10.73M USD. This makes BTAI a Nano Cap stock.
How many employees does BIOXCEL THERAPEUTICS INC have?
BIOXCEL THERAPEUTICS INC (BTAI) currently has 37 employees.
What are the support and resistance levels for BIOXCEL THERAPEUTICS INC (BTAI) stock?
BIOXCEL THERAPEUTICS INC (BTAI) has a support level at 1.56 and a resistance level at 1.85. Check the full technical report for a detailed analysis of BTAI support and resistance levels.
Is BIOXCEL THERAPEUTICS INC (BTAI) expected to grow?
The Revenue of BIOXCEL THERAPEUTICS INC (BTAI) is expected to decline by -15.93% in the next year. Check the estimates tab for more information on the BTAI EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BIOXCEL THERAPEUTICS INC (BTAI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BTAI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BTAI, evaluating the profitability, health, valuation and growth aspects
- BIOXCEL THERAPEUTICS INC (BTAI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIOXCEL THERAPEUTICS INC (BTAI) Sales and EPS estimates to see what analysts future expectations are.
- BIOXCEL THERAPEUTICS INC (BTAI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIOXCEL THERAPEUTICS INC (BTAI) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIOXCEL THERAPEUTICS INC (BTAI) Stock Chart to make your own analysis
- BIOXCEL THERAPEUTICS INC (BTAI) Latest news and press-releases to stay up to date.
Does BIOXCEL THERAPEUTICS INC (BTAI) stock pay dividends?
BTAI does not pay a dividend.
When does BIOXCEL THERAPEUTICS INC (BTAI) report earnings?
BIOXCEL THERAPEUTICS INC (BTAI) will report earnings on 2025-08-04.
What is the Price/Earnings (PE) ratio of BIOXCEL THERAPEUTICS INC (BTAI)?
BIOXCEL THERAPEUTICS INC (BTAI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-13.55).
What is the Short Interest ratio of BIOXCEL THERAPEUTICS INC (BTAI) stock?
The outstanding short interest for BIOXCEL THERAPEUTICS INC (BTAI) is 9.32% of its float. Check the ownership tab for more information on the BTAI short interest.
BTAI Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to BTAI. When comparing the yearly performance of all stocks, BTAI is a bad performer in the overall market: 96.99% of all stocks are doing better.
BTAI Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to BTAI. BTAI may be in some trouble as it scores bad on both profitability and health.
BTAI Financial Highlights
Over the last trailing twelve months BTAI reported a non-GAAP Earnings per Share(EPS) of -13.55. The EPS increased by 83.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -103.88% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BTAI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 75% to BTAI. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 66.91% and a revenue growth -15.93% for BTAI